Antibodies to the cytoplasm, cell membrane and nuclear membrane of malignant neoplasms in pooled normal human polyspecific immunoglobulin G.
IVIg is a preparation of normal polyspecific IgG obtained from pooled plasma of a large number of healthy donors. IVIg treatment of patients with chronic lymphocytic leukemia induced a reduction in the total number of lymphocytes in the peripheral blood. Regression of Kaposi's sarcoma was also noted in an HIV patient treated with IVIg. The aim of this study was to determine whether F(ab')2 prepared from IVIg binds to cellular structures of different tumor tissues. Biotinylated F(ab')2 was prepared from 3 different preparations of IVIg and from affinity purified IgG from a patient with multiple myeloma. Direct immunohistochemistry using a streptavidin peroxidase staining method was performed on biopsy samples of 18 different tumor tissues. Positive staining of the cytoplasm, cell membrane and nuclear membrane of several types of malignant tumors by F(ab')2 from IVIg was immunohistochemically demonstrated. Nuclear staining of tumor cells by IVIg was rare. IVIg bound to different tumors of epithelial origin, especially colon carcinoma, breast carcinoma and squamous cell carcinoma of the lung. Malignant tumors of mesenchymal origin such as leiomyosarcoma have also demonstrated positive staining by IVIg. IVIg contains antibodies to the cytoplasm, nuclear membrane and cell membrane of different malignant tumors especially of epithelial origin. This binding might provide a basis for the assumption that IVIg treatment of cancer patients may induce antibody dependent cell mediated cytotoxicity response against tumors, and implies that it can be potentially beneficial as adjuvant treatment of malignant diseases.
Bar-Dayan
Y
Y
Department of Medicine and Research Unit of Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.
Barshack
I
I
Blank
M
M
Goldberg
I
I
Levy
Y
Y
Kopolovic
J
J
Fishman
P
P
Shoenfeld
Y
Y
D000915:Antibody Affinity; D000918:Antibody Specificity; D001943:Breast Neoplasms / Q000276:immunology; D002462:Cell Membrane / Q000276:immunology*; D003110:Colonic Neoplasms / Q000276:immunology; D003593:Cytoplasm / Q000276:immunology*; D005260:Female; D006689:Hodgkin Disease / Q000276:immunology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000276:immunology; D007074:Immunoglobulin G / Q000276:immunology*; D016756:Immunoglobulins, Intravenous / Q000032:analysis / Q000276:immunology; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000276:immunology; D016393:Lymphoma, B-Cell / Q000276:immunology; D008545:Melanoma / Q000276:immunology; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D009685:Nuclear Envelope / Q000276:immunology*; D012516:Osteosarcoma / Q000276:immunology; D013945:Thymoma / Q000276:immunology
D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous